Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study

Mark Gurnell, Christian Domingo, Klaus F Rabe, Andrew Menzies-Gow, David Price, Guy Brusselle, Michael E Wechsler, Changming Xia, Michel Djandji, Rebecca Gall, Juby A. JacobNara, Paul J. Rowe, Yamo Deniz, Shahid Siddiqui

Research output: Contribution to conferenceAbstractpeer-review

Original languageEnglish
Publication statusAccepted/In press - 28 Jul 2022
Event17th Annual Deutscher Allergiekongress (DAK) 2022 - RheinMain Congress Center, Wiesbaden, Germany
Duration: 8 Sept 202210 Sept 2022
Conference number: 17


Conference17th Annual Deutscher Allergiekongress (DAK) 2022
Abbreviated title17th Annual Deutscher Allergiekongress (DAK) 2022
Internet address

Bibliographical note

Acknowledgments and funding sources
Data first presented at the 118th International Conference of the American Thoracic Society (ATS 2022); San Francisco, CA, USA; May 13–18, 2022. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Anthony Aggidis, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good
Publication Practice guideline. Alternate presenters: Anne Atenhan and Mayank Thakur.

Cite this